[(1~{S},2~{R},4~{R},6~{S},8~{R})-8-[5-methyl-2,4-bis(oxidanylidene)pyrimidin-1-yl]-6-oxidanyl-9-oxatricyclo[4.3.0.0^{2,4}]nonan-2-yl] dihydrogen phosphate
[(1~{S},2~{R},4~{R},6~{S},8~{R})-8-(2-azanyl-6-oxidanylidene-1~{H}-purin-9-yl)-6-oxidanyl-9-oxatricyclo[4.3.0.0^{2,4}]nonan-2-yl] dihydrogen phosphate
[(1~{S},2~{R},4~{R},6~{S},8~{R})-8-(4-azanyl-5-methyl-2-oxidanylidene-pyrimidin-1-yl)-6-oxidanyl-9-oxatricyclo[4.3.0.0^{2,4}]nonan-2-yl] dihydrogen phosphate
(2R,3aS,4aR,5aR,5bS)-2-(6-amino-9H-purin-9-yl)-3a-hydroxyhexahydrocyclopropa[4,5]cyclopenta[1,2-b]furan-5a(4H)-yl dihydrogen phosphate
NMR solution structure of tricyclo-DNA containing duplexes: insight into enhanced thermal stability and nuclease resistance.
Tc-DNA (5'-(*(TCJ)P*(TTK)P*(TCJ)P*(TCS)P*(TCS)P*(TCJ)P*(TTK)P*(TTK)P*(TCY)P*(TCJ))-3')
RNA (5'-R(*GP*UP*AP*AP*GP*CP*CP*GP*AP*G)-3')
structures with the least restraint violations
0.5 mM tc-DNA/RNA, 50 mM NaCl, 10 mM NaH2PO4, 100% D2O
0.5 mM tc-DNA/RNA, 50 mM NaCl, 10 mM NaH2PO4, 90% H2O/10% D2O
Brunger, Adams, Clore, Gros, Nilges and Read
Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
Tc-DNA (5'-(*(TCJ)P*(TTK)P*(TCJ)P*(TCS)P*(TCS)P*(TCJ)P*(TTK)P*(TTK)P*(TCY)P*(TCJ))-3'), RNA (5'-R(*GP*UP*AP*AP*GP*CP*CP*GP*AP*G)-3')
tricyclo-DNA, Modified nucleic acids, Modified oligonucleotide, Tc-DNA, DNA-RNA HYBRID